Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (351-360 of 636) with videos related to

Pageof 64
Sort By:
Journal of Hepatology|November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb studyStephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
Hepatology (Baltimore, Md.)|April 30, 2019
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver ForumAmanda Cheung, Brent A Neuschwander-Tetri, David E Kleiner, et al.
Hepatology Communications|June 19, 2026
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratificationPhilip N Newsome, Claudio Sartini, Heather L Morris, et al.
Alimentary Pharmacology & Therapeutics|January 18, 2025
Head-to-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective StudyFederica Tavaglione, Maral Amangurbanova, Alexander H Yang, et al.
Journal of Hepatology|March 25, 2018
Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patientsAlice M Turner, Jan Stolk, Robert Bals, et al.
The American Journal of Gastroenterology|June 11, 2025
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver diseaseA Sidney Barritt, Elliot B Tapper, Philip N Newsome, et al.
Gastroenterology|August 17, 2010
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver diseaseNaga Chalasani, Xiuqing Guo, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|August 29, 2022
Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASHDarren Jun Hao Tan, Veronica Wendy Setiawan, Cheng Han Ng, et al.
Hepatology (Baltimore, Md.)|May 21, 2013
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patientsMazen Noureddin, Katherine P Yates, Ivana A Vaughn, et al.
Radiology|November 1, 2022
MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical TrialsMarybeth A Nedrud, Mohammad Chaudhry, Michael S Middleton, et al.
Pageof 64

Showing results (351-360 of 636) with videos related to

Sort By:
Pageof 64
Journal of Hepatology|November 8, 2019
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb studyStephen A Harrison, Naim Alkhouri, Beth A Davison, et al.
Hepatology (Baltimore, Md.)|April 30, 2019
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver ForumAmanda Cheung, Brent A Neuschwander-Tetri, David E Kleiner, et al.
Hepatology Communications|June 19, 2026
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratificationPhilip N Newsome, Claudio Sartini, Heather L Morris, et al.
Alimentary Pharmacology & Therapeutics|January 18, 2025
Head-to-Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective StudyFederica Tavaglione, Maral Amangurbanova, Alexander H Yang, et al.
Journal of Hepatology|March 25, 2018
Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patientsAlice M Turner, Jan Stolk, Robert Bals, et al.
The American Journal of Gastroenterology|June 11, 2025
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver diseaseA Sidney Barritt, Elliot B Tapper, Philip N Newsome, et al.
Gastroenterology|August 17, 2010
Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver diseaseNaga Chalasani, Xiuqing Guo, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|August 29, 2022
Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASHDarren Jun Hao Tan, Veronica Wendy Setiawan, Cheng Han Ng, et al.
Hepatology (Baltimore, Md.)|May 21, 2013
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patientsMazen Noureddin, Katherine P Yates, Ivana A Vaughn, et al.
Radiology|November 1, 2022
MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical TrialsMarybeth A Nedrud, Mohammad Chaudhry, Michael S Middleton, et al.
Pageof 64